OakChart

Veru Inc

VERUHealthcare·Biotechnology·USA·Nano·NASD·Nov 11 • 3:59 PM ET

2.14+0.02 (0.94%)
2026-11-12 00:08 CET
Market cap
36.15 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-14.11 USD m
Free cash flow, TTM
-26.04 USD m
EPS diluted, TTM
-0.61
P/E
-
Compare

Price

VERU against its 20, 50 and 200-day averages
2050200beat
2.004.006.0046.4M92.9MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26VERUclose 2.1420-day 2.2350-day 2.38200-day 2.482.1452w high

70.8% under the 52-week high of 7.33 on 4 Jun 2026. 52-week low 2.04 on 5 Nov 2026. Last 15 sessions, 16.2% high to low

Volume 0.20× normal · the line is the 50-bar volume average

Profile

VERU
52-week range, 2% of the way up
2.047.33

Veru, Inc. is a late clinical stage biopharmaceutical company focused on developing novel medicines and treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. The company was founded by William R. Gargiulo, Jr. and O. B. Parrish in 1971 and is headquartered in Miami, FL.

Employees20
IPOJul 19, 1990
Beta-1.20
ATR, 14d0.12
Rel volume0.20
Short float10.00%
Insider own12.10%
Inst own17.16%

Snapshot

6 groups

Valuation

Index-
Market Cap36.49M
Enterprise Value13.38M
Income-14.11M
Sales0.00M
Book/sh1.66
Cash/sh1.51
Dividend Est.-
Dividend TTM-
Dividend Ex-DateApr 28, 2014
Dividend Gr. 3/5Y- -
Payout-
Employees20
IPOJul 19, 1990

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B1.29
P/C1.41
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio4.42
Current Ratio4.42
Debt/Eq0.09
LT Debt/Eq0.07
Option/ShortYes / Yes

Earnings

EPS (ttm)-0.61
EPS next Y-0.83
EPS next Q-0.25
EPS this Y47.96%
EPS next Y-2.89%
EPS next 5Y33.14%
EPS past 3/5Y50.51% 14.86%
Sales past 3/5Y- -
EPS Y/Y TTM68.62%
Sales Y/Y TTM-100.00%
EPS Q/Q39.40%
Sales Q/Q-
EarningsAug 10 BMO
EPS/Sales Surpr.6.25% -

Ownership

Insider Own12.10%
Insider Trans0.09%
Inst Own17.16%
Inst Trans-6.71%
ROA-43.85%
ROE-64.54%
ROIC-46.59%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA20-4.01%
SMA50-9.90%
SMA200-13.58%
Trades-

Technical

Shs Outstand17.05M
Shs Float14.99M
Short Float10.00%
Short Ratio7.74
Short Interest1.50M
52W High7.33 -70.80%
52W Low2.04 4.90%
Volatility6.13% 6.26%
ATR (14)0.12
RSI (14)42.43
Beta-1.20
Rel Volume0.20
Avg Volume193.61K
Volume38,949

Performance

Perf Week-2.73%
Perf Month-2.28%
Perf Quarter-20.74%
Perf Half Y-5.31%
Perf YTD0.00%
Perf Year-18.32%
Perf 3Y-76.69%
Perf 5Y-97.60%
Perf 10Y-74.53%
Recom1.00
Target Price25.67
Prev Close2.12
Price2.14
Change %0.94%

Analyst ratings

latest 9 of 9
DateActionAnalystRating changeTargetImplied
Dec 18, 2025InitiatedCCanaccord GenuityBuy$25+1,068.2%
May 14, 2024InitiatedRB. Riley SecuritiesBuy$5+133.6%
Mar 28, 2024InitiatedRRaymond JamesOutperform$3+40.2%
Jun 07, 2023UpgradeJJefferiesUnderperform → Hold$1-53.3%
Apr 13, 2021InitiatedJJefferiesBuy$19+787.9%
Feb 09, 2021ReiteratedHH.C. WainwrightBuy$12 → $17+694.4%
Jan 21, 2020ReiteratedHH.C. WainwrightBuy$4.50 → $6+180.4%
Mar 20, 2019InitiatedOOppenheimerOutperform$5+133.6%
Jul 03, 2018InitiatedMMaxim GroupBuy

Peers

Mkt cap
TickerCompanyMkt cap
SKYESkye Bioscience Inc4.06M
ALTAltimmune Inc375.41M
BMEABiomea Fusion Inc44.28M
GUTSFractyl Health Inc11.68M
MTVAMetaVia Inc9.49M
VKTXViking Therapeutics Inc3.63B
SRRKScholar Rock Holding Corp5.68B
PTNPalatin Technologies Inc12.22M
KLRAKailera Therapeutics Inc1.87B
GPCRStructure Therapeutics Inc ADR1.49B

Insider trading

1 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
BARNETTE K GARYChief Scientific OfficerAug 13 '26Buy2.691,8004,8422,300Aug 17 04:26 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWCiShares Micro-Cap ETFAUM: 1.22B

News

latest 14 of 200

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-08-10-0.300-0.320-0.3000.000.002
2026Q22026-05-13-0.130-0.285-0.1340.000.002
2026Q12026-02-11-0.260-0.472-0.2630.000.002
2025Q42025-12-170.050-0.3650.0890.000.002
2025Q32025-08-12-0.500-0.534-0.5000.000.003
2025Q22025-05-08-0.500-0.625-0.5400.000.734
2025Q12025-02-13-0.600-0.760-0.3240.003.025
2024Q42024-12-02-0.620-0.740-0.5835.503.565
2024Q32024-08-08-0.700-0.580-0.7493.953.505
2024Q22024-05-08-0.700-0.533-0.6854.103.003
2024Q12024-02-08-0.800-1.200-0.8232.103.901
2023Q42023-12-14-2.600-2.350-1.1833.863.952
2023Q32023-08-100.700-2.033-0.7553.346.223
2023Q22023-05-11-4.800-3.325-4.7996.594.334
2023Q12023-02-09-4.600-3.767-4.5732.515.073
2022Q42022-12-05-5.100-3.025-5.1072.5911.554

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-1.900-1.900-1.89831.8032.26
2020FY-2.800-1.550-2.84242.5941.44
2021FY0.9000.5000.88261.2663.69
2022FY-10.500-8.450-10.48939.3548.34
2023FY-11.000-10.650-10.96316.3016.37
2024FY-2.820-2.980-2.80316.3013.75
2025FY-1.550-1.130-1.5500.000.00
2026FY--0.807--0.00
2027FY--0.830--0.00
2028FY--0.463--12.50
2029FY--0.600--0.00
2030FY--0.425--7.50

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-10-133000.000.000.00
2026Q4S2026-10-052000.000.000.00
2026Q4S2026-09-181000.000.000.00
2026Q4S2026-08-102000.000.000.00
2026Q4S2026-05-132000.000.000.00
2026Q4S2026-02-112000.000.000.00
2026Q4S2026-01-272000.000.000.00
2026Q4S2025-12-311000.000.000.00
2026Q4S2025-12-172000.000.000.00
2026Q4S2025-12-112000.000.000.00
2026Q4S2025-11-113000.000.000.00
2026Q4S2025-11-103000.000.000.00
2026Q4S2025-11-093000.000.000.00
2026Q4S2025-11-083000.000.000.00

Estimate history

EPS, annual-2.484-4.444-1.898-2.8420.882-10.489-10.963-2.803-1.272-0.6109
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.749-0.583-0.324-0.54-0.50.089-0.263-0.134-0.303
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual13.65615.86431.80342.59261.2639.35416.297000
Period201720182019202020212022202320242025TTM
Sales, quarterly3.9546.6570000000
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual5.3215.5286.5046.9867.9978.2699.17814.63814.6517.05
Period201720182019202020212022202320242025MRQ
Shares, quarterly14.63814.63814.63814.65814.6514.6516.0516.0517.05
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.000.0016.3039.3561.2642.5931.8015.86
Cost of Goods Sold Incl. D&A0.110.150.278.808.8313.4512.1210.467.36
Gross Profit-0.11-0.15-0.277.4930.5247.8130.4721.358.51
Selling, General and Administrative Excl. Other27.7035.3837.12103.10114.0153.2531.1227.7825.39
Research and Development11.7615.5912.7851.2070.9132.6916.9413.7410.85
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-27.82-35.53-37.39-95.61-83.49-5.44-0.65-6.44-16.89
Interest Expense0.000.000.612.434.374.894.624.712.95
Unusual Expense-4.38-8.300.180.94-3.563.6714.661.20-0.89
Net Income Before Taxes-14.11-15.68-35.26-92.67-83.804.27-20.05-12.32-23.07
Income Taxes0.000.000.000.480.24-3.13-1.08-0.300.87
Consolidated Net Income-14.11-15.68-35.26-93.15-84.047.39-18.97-12.02-23.94
Net Income From Continuing Operations-14.11-15.68-35.26-93.15-84.047.39-18.97-12.02-23.94
Net Income-14.11-18.62-37.80-93.15-84.047.39-18.97-12.02-23.94
EPS (Recurring)-0.75-1.67-2.79-10.89-10.801.19-1.31-1.77-4.56
EPS (Basic, Before Extraordinaries)-0.61-1.27-2.80-10.96-10.490.97-2.84-1.90-4.44
EPS (Diluted)-0.61-1.27-2.80-10.96-10.490.88-2.84-1.90-4.44
EBITDA-27.70-35.38-37.12-95.34-83.28-4.840.14-5.96-16.43
Non-Operating Income (Expense)9.3211.552.316.300.5018.26-0.130.02-4.13
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense7.938.1013.6413.928.743.952.051.481.21
Price To Earnings Ratio-----83.73---
Price To Sales Ratio--6.143.7523.4511.674.114.304.82
Gross Margin---45.9977.5578.0571.5467.1253.62
Operating Margin----586.65-212.14-8.88-1.52-20.24-106.44
Net Margin----571.60-213.5512.07-44.55-37.79-150.89
Shares Outstanding17.0514.6514.649.188.278.006.996.505.53
Market Capitalization36.1536.15112.5764.16927.46682.14183.04140.4877.74

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.000.000.000.000.000.000.006.66
Cost of Goods Sold Incl. D&A0.030.030.030.030.030.030.063.97
Gross Profit-0.03-0.03-0.03-0.03-0.03-0.03-0.062.69
Selling, General and Administrative Excl. Other7.697.195.407.438.009.0710.8811.09
Research and Development4.353.151.342.923.023.935.723.29
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-7.71-7.22-5.42-7.46-8.03-9.10-10.94-8.40
Interest Expense0.000.000.000.000.000.00-0.17
Unusual Expense-0.55-3.930.12-0.030.000.00-8.28-0.17
Net Income Before Taxes-6.99-3.09-5.331.30-7.32-7.85-1.81-8.08
Income Taxes0.000.000.000.000.000.000.000.45
Consolidated Net Income-6.99-3.09-5.331.30-7.32-7.85-1.81-8.53
Net Income From Continuing Operations-6.99-3.09-5.331.30-7.32-7.85-1.81-8.53
Net Income-6.99-3.09-5.331.30-7.33-7.90-4.74-8.53
EPS (Recurring)-0.32-0.25-0.260.09-0.50-0.54-0.72-0.59
EPS (Basic, Before Extraordinaries)-0.30-0.13-0.260.09-0.50-0.54-0.32-0.58
EPS (Diluted)-0.30-0.13-0.260.09-0.50-0.54-0.32-0.58
EBITDA-7.69-7.19-5.40-7.43-8.00-9.07-10.88-8.33
Non-Operating Income (Expense)0.180.200.218.740.711.240.860.32
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.580.400.166.790.302.222.672.55
Price To Sales Ratio----12.816.766.466.67
Gross Margin-------40.37
Operating Margin--------126.19
Net Margin--------128.15
Shares Outstanding17.0516.0516.0514.6514.6514.6614.6414.64
Market Capitalization36.1535.4734.3555.7085.2471.8495.22112.57

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments18.3225.669.6380.19122.3613.596.303.763.28
Short Term Receivables0.000.004.513.5513.795.235.023.973.42
Inventories0.000.006.708.625.576.703.652.302.77
Other Current Assets0.609.562.1011.6410.031.491.841.150.83
Total Current Assets18.9235.2222.93104.00151.7527.0116.8111.1810.30
Net Property, Plant & Equipment3.113.735.995.971.561.670.350.400.56
Total Investments and Advances0.000.000.000.000.000.000.000.000.00
Long-Term Note Receivable--0.000.71-0.000.000.007.84
Intangible Assets6.886.886.8810.8610.9312.6327.0527.3627.63
Deferred Tax Assets0.000.4013.1612.9713.029.478.438.548.83
Other Assets0.9314.581.510.850.880.770.990.970.19
Total Assets29.8460.8150.47135.36178.1551.5453.6348.4555.34
Short Term Debt Incl. Current Port. of LT Debt0.761.761.902.133.747.555.396.690.00
Accounts Payable3.122.2612.9322.003.412.813.123.232.69
Other Current Liabilities3.907.852.9814.588.614.365.513.632.80
Total Current Liabilities7.7911.8717.8138.7115.7714.7314.0213.555.49
Long Term Debt2.3611.7612.5013.7510.016.626.734.460.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Deferred Tax Liabilities0.000.400.450.080.060.070.300.84-
Other Liabilities1.364.480.030.020.010.010.250.121.40
Total Liabilities11.5028.5030.8052.5625.8521.4321.3018.976.88
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity18.3332.3219.6882.80152.2930.1132.3329.4848.45
Total Shareholders Equity18.3332.3219.6882.80152.2930.1132.3329.4848.45
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity18.3332.3219.6882.80152.2930.1132.3329.4848.45
Total Liabilities & Stockholders Equity29.8460.8150.47135.36178.1551.5453.6348.4555.34
Book Value Per Share1.252.212.1410.0119.044.314.975.339.11
Tangible Book Value Per Share0.781.741.398.7017.682.500.810.383.91
Full-Time Employees20210189233252339386171175
Price to Book Ratio1.273.483.0011.474.486.084.342.172.53
Return on Assets-34.60-63.37-99.84-53.616.44-36.08-23.54-46.14-14.07
Return on Equity-61.92-135.63-185.35-71.508.11-60.77-38.88-61.43-16.05
Return on Invested Capital-90.00-85.77-289.45-87.054.56-51.66-30.76-70.54-13.65
Quick Ratio2.432.970.912.469.271.380.940.661.37
Current Ratio2.432.971.292.699.621.831.200.831.88

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-13.61-22.73-37.80-93.15-84.047.39-18.97-12.02-23.94
Depreciation0.110.150.270.270.210.590.780.470.45
Other Funds (Non Cash)-9.70-3.3415.2619.8410.10-12.7121.868.067.77
Funds from Operations-23.20-25.91-21.90-72.86-73.65-8.292.42-3.92-15.09
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-2.84-4.130.22-15.1526.15-7.28-4.35-1.563.54
Cash from Operating Activities-26.04-30.04-21.68-88.01-47.51-15.57-1.93-5.49-11.55
Capital Expenditures0.00-0.00-0.16-0.67-0.73-0.38-0.11-0.11-0.05
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses6.6324.750.307.005.0015.000.000.000.00
Purchase or Sale of Investments4.970.390.000.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.000.000.000.00
Sale Or Maturity of Investments4.970.390.000.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities11.6025.140.156.334.2714.62-0.11-0.11-0.05
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock23.370.0036.9610.981.08109.7413.7713.062.99
Repurchase of Common Pref Stock0.000.000.000.000.000.00-0.050.00-0.08
Sale of Common Pref Stock23.370.0036.9610.981.08109.7413.8213.063.07
Proceedsfrom Stock Options23.370.0036.9610.590.00107.9613.4012.733.00
Issuance or Reduction of Debt, Net0.000.00-0.130.13-0.01-0.02-4.44-4.949.09
Change in Long Term Debt0.000.00-0.130.13-0.01-0.02-4.44-4.949.09
Issuance of Long Term Debt0.000.000.001.430.001.060.840.009.73
Reduction of Long Term Debt0.000.00-0.13-1.29-0.01-1.08-5.27-4.94-0.64
Net Financing Active Other Cash Flow-0.05-4.220.000.000.000.000.000.000.00
Other Financing Activities Uses-0.05-4.220.000.000.000.000.000.000.00
Cash from Financing Activities23.31-4.2236.8311.111.07109.729.338.1312.08
Net Change in Cash8.87-9.1215.29-70.57-42.17108.777.292.540.48
Free Cash Flow-26.04-30.04-21.84-88.68-48.24-15.95-2.04-5.59-11.60
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit--0.000.370.180.08-3.57-1.26-0.440.63

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments25.7930.7635.4018.3215.0120.02
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets1.442.591.410.601.181.36
Total Current Assets27.2333.3636.8118.9216.1921.38
Net Property, Plant & Equipment2.622.792.953.113.273.43
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets6.886.886.886.886.886.88
Deferred Tax Assets---0.00--
Other Assets0.300.060.930.930.990.99
Total Assets37.0343.0847.5729.8427.3332.67
Short Term Debt Incl. Current Port. of LT Debt0.780.770.760.760.750.75
Accounts Payable1.712.071.523.122.542.21
Other Current Liabilities3.672.554.853.903.392.67
Total Current Liabilities6.165.397.137.796.685.62
Long Term Debt1.912.062.212.362.502.64
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities---0.00--
Other Liabilities0.590.851.101.362.803.36
Total Liabilities8.658.3010.4411.5011.9911.62
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity28.3834.7937.1218.3315.3421.05
Total Shareholders Equity28.3834.7937.1218.3315.3421.05
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity28.3834.7937.1218.3315.3421.05
Total Liabilities & Stockholders Equity37.0343.0847.5729.8427.3332.67
Book Value Per Share1.662.172.311.251.051.44
Tangible Book Value Per Share1.261.741.880.780.580.97
Full-Time Employees---20--
Price to Book Ratio1.270.961.713.635.553.41
Return on Assets-43.85-38.13-43.95-34.60-55.49-55.83
Return on Equity-64.54-51.74-60.25-61.92-96.35-88.03
Return on Invested Capital-23.08-8.39-13.566.30-41.09-33.36
Quick Ratio4.426.195.162.432.423.80
Current Ratio4.426.195.162.432.423.80

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-6.99-2.74-5.331.45-7.33-7.90
Depreciation0.030.030.030.030.030.03
Other Funds (Non Cash)0.17-3.751.01-7.141.371.43
Funds from Operations-6.79-6.46-4.29-5.65-5.94-6.44
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital1.32-2.46-1.870.160.46-1.29
Cash from Operating Activities-5.47-8.91-6.17-5.49-5.48-7.74
Capital Expenditures0.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.350.006.280.471.15
Purchase or Sale of Investments1.803.170.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments1.803.170.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities1.803.520.006.280.471.15
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.000.0023.370.000.000.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.000.0023.370.000.000.00
Proceedsfrom Stock Options0.000.0023.370.000.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow-0.050.000.000.000.000.00
Other Financing Activities Uses-0.050.000.000.000.000.00
Cash from Financing Activities-0.050.0023.370.000.000.00
Net Change in Cash-3.72-5.3917.200.78-5.01-6.59
Free Cash Flow-5.47-8.91-6.17-5.49-5.48-7.74

Revenue breakdown

FC2 Female Condom2024: 16.89M
Brazil2024: 2.76M
MOZAMBIQUE2024: 2.17M
Other Geographical Areas2024: 4.70M
South Africa2024: 1.90M
United States2024: 5.35M
Total Pharmaceutical Preparations revenue2024: 16.89M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3010.00%1.5M15.0M219.48K
2026-10-159.78%1.5M15.0M237.07K
2026-09-309.36%1.4M15.0M243.70K
2026-09-1510.05%1.5M15.0M285.09K
2026-08-318.99%1.3M15.0M1.98M
2026-08-149.45%1.4M14.9M2.00M
2026-07-319.91%1.4M14.0M1.95M
2026-07-1510.05%1.4M14.0M1.95M
2026-06-304.88%0.7M14.0M1.87M
2026-06-156.75%0.9M14.0M1.80M
2026-05-294.04%0.6M14.0M58.72K
2026-05-154.24%0.6M14.0M57.00K
2026-04-304.13%0.6M14.0M62.91K
2026-04-154.69%0.7M14.0M75.53K
2026-03-314.79%0.7M14.0M87.57K
2026-03-135.15%0.7M14.0M130.31K
2026-02-275.25%0.7M14.0M134.61K
2026-02-135.33%0.7M14.0M145.96K
2026-01-305.51%0.8M14.0M160.08K
2026-01-155.25%0.7M14.0M171.23K

Option chain

expiry 2026-11-13
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call0.501.302.301.620.0007.001.000.968-0.0480.000
call1.000.851.401.1717.1380.004.000.936-0.0470.000
call1.500.350.900.6710.4055.000.000.883-0.0400.000
call2.000.000.750.0011.9260.000.000.663-0.1320.001
call2.500.000.800.0014.6660.000.000.644-0.2260.001
call3.000.000.300.089.0441.000.000.418-0.1460.001
call3.500.000.050.0017.1440.000.000.603-0.2520.001
call4.000.000.050.006.0890.000.000.124-0.0480.000
call4.500.001.000.007.1970.000.000.115-0.0580.000
call5.000.000.050.0019.9510.000.000.574-0.2980.001
put0.500.000.050.000.0000.000.000.0000.0000.000
put1.000.000.050.008.2500.000.00-0.066-0.0400.000
put1.500.000.050.0020.9930.000.00-0.156-0.1910.000
put2.000.000.400.058.0892560.00-0.337-0.1320.001
put2.500.100.750.008.5570.000.00-0.356-0.2260.001
put3.000.501.200.009.7250.000.00-0.582-0.1460.001
put3.501.001.750.0012.0500.000.00-0.860-0.0500.000
put4.001.502.200.0012.3940.000.00-0.875-0.0540.000
put4.502.002.700.0013.3780.000.00-0.885-0.0570.000
put5.002.403.400.0017.5830.000.00-0.892-0.0600.000

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-09-088-KCurrent report2026-09-08SEC
2026-08-174Statement of changes in beneficial ownership of securities2026-08-13SEC
2026-08-1010-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-108-KCurrent report2026-08-10SEC
2026-07-028-KCurrent report2026-07-02SEC
2026-07-02424B5SEC
2026-06-048-KCurrent report2026-06-02SEC
2026-05-13S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-05-1310-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-138-KCurrent report2026-05-13SEC
2026-05-064Statement of changes in beneficial ownership of securities2026-05-04SEC
2026-05-064Statement of changes in beneficial ownership of securities2026-05-04SEC
2026-05-064Statement of changes in beneficial ownership of securities2026-05-04SEC
2026-05-064Statement of changes in beneficial ownership of securities2026-05-04SEC
2026-05-064Statement of changes in beneficial ownership of securities2026-05-04SEC
2026-05-064Statement of changes in beneficial ownership of securities2026-05-04SEC
2026-05-064Statement of changes in beneficial ownership of securities2026-05-04SEC
2026-05-064Statement of changes in beneficial ownership of securities2026-05-04SEC
2026-04-15EFFECTEffectiveness filing by commission orderSEC
2026-04-15EFFECTEffectiveness filing by commission orderSEC
2026-04-13CORRESPSEC
2026-04-13CORRESPSEC
2026-04-13UPLOADUpload SubmissionSEC
2026-04-13UPLOADUpload SubmissionSEC
2026-04-07S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-04-07S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-03-138-KCurrent report2026-03-12SEC
2026-02-17SCHEDULE 13GSEC
2026-02-1110-QQuarterly report pursuant to Section 13 or 15(d)2025-12-31SEC
2026-02-118-KCurrent report2026-02-11SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-084.84K100
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
VANGUARD CAPITAL MANAGEMENT LLC4.35%
Alyeska Investment Group, L.P.1.49%
OPPENHEIMER & CO INC1.15%
GEODE CAPITAL MANAGEMENT, LLC1.14%
BlackRock, Inc.1.04%
RENAISSANCE TECHNOLOGIES LLC1.02%
GSA CAPITAL PARTNERS LLP0.98%
Summit Financial, LLC0.88%
JANE STREET GROUP, LLC0.80%
FNY Investment Advisers, LLC0.65%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND3.31%
VANGUARD EXTENDED MARKET INDEX FUND0.99%
Fidelity Extended Market Index Fund0.60%
iShares Micro-Cap ETF0.31%
Fidelity Total Market Index Fund0.14%
Fidelity Series Total Market Index Fund0.12%
VANGUARD BALANCED INDEX FUND0.05%
Schwab Total Stock Market Index Fund0.04%
Fidelity Nasdaq Composite Index Fund0.02%
1290 VT Micro Cap Portfolio0.02%

OakChart. VERU. Cached 15 minutes.